Gilead Sciences, the Trump administration, and the Global Fund have joined in partnership to bring lenacapavir, the new twice-yearly injectable prevention tool against HIV/AIDS, to two million persons at-risk in ten African countries in three years. Emily Gibbons, Gilead Sciences, explains the back story—the determined work of the previous two and a half years to plan an effective launch that would have speed, support from communities, access to affordable volumes of the medicine, and implementation to deliver. She also speaks to the challenges ahead to see lenacapavir reach a meaningful scale to drive HIV infections down, especially among the most vulnerable populations.
